Skip to content

RNTX RNTX Income Tax

Income Tax at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$561M+10.2%
Gilead Sciences logo
Gilead SciencesGILD
$559M+67.4%
AbbVie logo
AbbVieABBV
$342M-8.1%
CTO
Citius Oncology, Inc.CTOR
-$231.21K-188%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$621K-31.1%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$0

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M+6.8%
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Cash & equivalents$4.4M-40.2%
Total debt$48.0K0.0%
Total equity$6.9M-63.0%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%
CapEx-
Free cash flow-$6.3M

Valuation

See full
Market cap$88.96M+164%

Returns & leverage

See full
Return on equity-123.3%+86.1pp
Debt / equity0.0×
Current ratio0.4×-1.0×

Where this comes from

Reported directly by RNTX in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The official record: RNTX’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about RNTX's income tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RNTX's income tax?
RNTX (RNTX) reported income tax of -$178K in Q4 2025.
How has RNTX's income tax changed year-over-year?
RNTX's income tax increased by 53.9% year-over-year, from -$386K to -$178K.
What does income tax mean?
Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.